Farallon Capital Management LLC Has $178.35 Million Position in Lantheus Holdings, Inc. $LNTH

Farallon Capital Management LLC decreased its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 48.3% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 3,477,227 shares of the medical equipment provider’s stock after selling 3,245,000 shares during the quarter. Farallon Capital Management LLC owned 0.05% of Lantheus worth $178,347,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Brevan Howard Capital Management LP grew its stake in Lantheus by 496.5% during the third quarter. Brevan Howard Capital Management LP now owns 39,747 shares of the medical equipment provider’s stock worth $2,039,000 after buying an additional 33,084 shares during the last quarter. California Public Employees Retirement System increased its holdings in Lantheus by 1.2% during the 3rd quarter. California Public Employees Retirement System now owns 120,627 shares of the medical equipment provider’s stock valued at $6,187,000 after purchasing an additional 1,384 shares in the last quarter. Boothbay Fund Management LLC bought a new position in Lantheus in the 3rd quarter valued at $407,000. Ameriprise Financial Inc. raised its position in Lantheus by 14.0% in the 3rd quarter. Ameriprise Financial Inc. now owns 249,864 shares of the medical equipment provider’s stock valued at $12,815,000 after purchasing an additional 30,706 shares during the last quarter. Finally, Creative Planning boosted its stake in Lantheus by 20.4% in the third quarter. Creative Planning now owns 27,725 shares of the medical equipment provider’s stock worth $1,422,000 after purchasing an additional 4,698 shares in the last quarter. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Lantheus Price Performance

Shares of LNTH stock opened at $79.49 on Monday. The company has a quick ratio of 2.51, a current ratio of 2.70 and a debt-to-equity ratio of 0.52. The firm has a market cap of $5.17 billion, a price-to-earnings ratio of 23.59 and a beta of -0.11. The stock has a 50-day moving average price of $70.53 and a 200 day moving average price of $61.82. Lantheus Holdings, Inc. has a 12 month low of $47.25 and a 12 month high of $108.91.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Thursday, February 26th. The medical equipment provider reported $1.67 EPS for the quarter, beating analysts’ consensus estimates of $1.17 by $0.50. Lantheus had a return on equity of 30.77% and a net margin of 15.15%.The business had revenue of $406.79 million during the quarter, compared to the consensus estimate of $367.03 million. During the same quarter in the prior year, the company posted $1.59 earnings per share. The firm’s revenue was up 4.0% on a year-over-year basis. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Research analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Analyst Ratings Changes

Several brokerages have recently commented on LNTH. Wall Street Zen cut Lantheus from a “strong-buy” rating to a “buy” rating in a report on Sunday. JonesTrading downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Friday, February 27th. Mizuho increased their price objective on shares of Lantheus from $72.00 to $85.00 and gave the stock an “outperform” rating in a report on Friday, February 27th. Citizens Jmp boosted their target price on shares of Lantheus from $73.00 to $78.00 and gave the stock a “market outperform” rating in a research note on Tuesday, February 24th. Finally, Weiss Ratings upgraded shares of Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, January 6th. Seven research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Lantheus currently has an average rating of “Moderate Buy” and a consensus price target of $82.17.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.